Updates

In unanimous fashion, the FDA AMDAC voted 21 to 0 that nirsevimab has a favorable benefit risk profile for the prevention of RSV lower respiratory tract disease (LRTD) in newborns and infants during their first RSV season.

Investigators state public health strategies should prioritize early detection of mental health needs and equitable access to it, as some Medicaid-enrolled children are not receiving mental health services following a firearm injury.

Following household COVID-19 transmissions for over 3 years, investigators found that 70.4% had a pediatric index case.

Semaglutide (Wegovy; Novo Nordisk) for obesity in adolescents, along with 2 other approved products containing semaglutide, are currently on the FDA’s drug shortages list, prompting the agency to warn patients and providers about drug compounding.